Cristina Larrosa

6PUBLICATIONS
13CO-AUTHORS
Nanotoxicology, health and safetyRadiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 04, 2026
Quantum-Capacitance Biosensing Enables Real-Time Monitoring of Naxitamab for Therapeutic Response Stratification in Neuroblastoma.

|Aug 01, 2024
Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes.

Cristina Larrosa, Soraya Mico, Mónica Ramos

|May 11, 2024
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.

Maite Gorostegui, Juan Pablo Muñoz, Sara Perez-Jaume

|Oct 14, 2023
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.

Juan Pablo Muñoz, Cristina Larrosa, Saray Chamorro

|Jul 29, 2023
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2.

Cristina Larrosa, Jaume Mora, Nai-Kong Cheung

|May 13, 2023
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.

Jaume Mora, Alicia Castañeda, Maite Gorostegui

Pageof 1

Frequent Collaborators

4 joint publications

Jaume Mora

3 joint publications

Sara Perez-Jaume

2 joint publications

Moira Garraus

2 joint publications

Lucas Krauel